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Background and purpose
Malignant gliomas, such as glioblastoma (GBM) and dif-
fuse intrinsic pontine gliomas (DIPG), are lethal brain
tumors in both adults and children. Indeed, brain tumors
are the leading cause of cancer-related mortality and
morbidity in children. Children with DIPG have one-year
progression-free survival rates below 25%, and median
overall survival of 9 to 10 months with current treatment.
Recent genetic studies have revealed that malignant
gliomas in children and young adults often show shared
missense mutations, which encodes the replication-
independent histone 3 variant H3.3. Approximately 30 %
of overall GBM and over 70% of DIPG cases harbor the
amino-acid substitution from lysine (K) to methionine (M)
at the position 27 of H3.3. The H3.3 K27M mutation in
DIPG is universally associated with shorter survival com-
pared with patients with non-mutated H3.3. We evaluated
whether H3.3-derived peptides that encompass the H3.3
K27M mutation can induce specific cytotoxic T lympho-
cyte (CTL) responses in human leukocyte antigen (HLA)-
A2+ CD8+ T cells.
Methods
For prediction of HLA-A2-binding epitopes, an algorithm
integrating peptide binding to HLA (NetMHC 3.4 server)
and a proteosomal cleavage site prediction system (http://
paproc.de/) was used. Four candidate peptides encompass-
ing different amino-acid positions around the H3.3 K27M
mutation were synthesized, and peptide-specific CTL lines
and clones were generated from peripheral blood
mononuclear cells of HLA-A2+ donors by in vitro stimula-
tion with each of the synthetic peptides.
Results
One of the 4 peptides (the H3.3.K27M epitope, hereafter)
induced CTL lines which recognized not only the syn-
thetic peptide loaded on T2 cells but also lysed HLA-A2+
DIPG cell lines which endogenously harbor the H3.3.
K27M mutation. On the other hand, CTL lines did not
react to HLA-A2+, H3.3 K27M mutation-negative cells or
HLA-A2-negative, H3.3 K27M mutation+ cells (Figure 1).
Furthermore, CTL clones with high and specific affinities
to HLA-A2-H3.3.K27M-tetramer were successfully
obtained (Figure 2), and a- and b-chain cDNAs from
high-affinity T cell receptors (TCR)s were cloned into a
lentiviral vector. Additional studies are underway to
determine antigen specificity, key epitope residues in the
epitope and possible cross-reactivity to naturally existing
variants using T cells transduced with the lentiviral vector
encoding the TCR. Assessments of in vivo immune
responses to the epitope peptide and preclinical confirma-
tion for absence of autoimmunity are also underway using
HLA-A2-transgenic mice.
Conclusions
These data provide us with a strong basis for developing
peptide-based vaccines as well as adoptive transfer therapy
using autologous T cells transduced with the TCR.
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